Every Form 4 that UnitedHealth Group Incorporated (UNH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow UNH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UNH filings page.
UnitedHealth Group (UNH) director Valerie C. Montgomery Rice, M.D. was granted 270 deferred stock units on 10/01/2025 as part of regular quarterly director compensation. The units are immediately vested but must be held until she leaves the board. After the grant, her reported beneficial ownership of common stock is 6,897 shares, held directly. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
This Form 4 reports that Charles D. Baker, a director of UnitedHealth Group Inc. (UNH), was granted 260 deferred stock units as director compensation on 10/01/2025. The units were granted at a $0 per-unit price and are described as immediately vested but required to be retained until the director leaves the Board. After the reported grant, the filing shows 1,516 shares (or equivalent units) beneficially owned by Mr. Baker. The form was signed by Faraz A. Choudhry, Attorney-in-Fact on 10/03/2025.
Michele J. Hooper, a director of UnitedHealth Group (UNH), was granted 162 deferred stock units on 10/01/2025 as regular quarterly director compensation. The grant was recorded at a reported price of $0 and increases her reported beneficial ownership to 40,877 shares following the transaction. The filing states the deferred stock units are immediately vested but must be retained until the director ends service on the Board. The Form 4 was signed by an attorney-in-fact and dated 10/03/2025.
John H. Noseworthy, a director of UnitedHealth Group Inc. (UNH), reported acquisition of 261 deferred stock units on 10/01/2025 as part of regular quarterly director compensation. The units were granted at $0 (deferred awards) and are immediately vested but must be held until the director leaves the Board. After the transaction, Dr. Noseworthy beneficially owns 6,693 shares (direct). The Form 4 was signed by attorney-in-fact Faraz A. Choudhry on 10/03/2025. The filing indicates this is a single reporting person filing and identifies the reporter as a Director of the issuer.
Timothy J. Noel, Chief Executive Officer, UHC, reported a non-derivative acquisition of common stock for UNITEDHEALTH GROUP INC (UNH) dated 09/23/2025. The transaction is coded A and is described as dividend equivalents paid on outstanding restricted stock units, which follow the same vesting terms as the underlying RSUs and are forfeited if the RSUs do not vest. The filing records a $0 price for the acquisition and shows 9,286.339 shares beneficially owned following the reported transaction(s). The form was signed by an attorney-in-fact on behalf of Mr. Noel on 09/25/2025.
Wayne S. DeVeydt, Chief Financial Officer of UnitedHealth Group Inc. (UNH), reported a non-derivative acquisition on 09/23/2025 of 66.899 shares of common stock. The filing states these shares represent dividend equivalents paid on outstanding restricted stock units and were recorded at a $0 price because they are dividend-equivalent awards rather than open-market purchases. After the transaction, Mr. DeVeydt beneficially owned 10,591.899 shares. The filing notes the dividend equivalents are subject to the same vesting and forfeiture terms as the underlying restricted stock units.
Kristen L. Gil, a director of UnitedHealth Group Inc. (UNH), reported a non-derivative acquisition on 09/23/2025 consisting of 7 shares credited as dividend equivalents on vested deferred stock units; these dividend equivalents vested immediately and follow the same terms as the underlying units. After the transaction Ms. Gil is shown as beneficially owning 1,738 shares directly and 3,800 shares indirectly through a trust. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/25/2025.
UnitedHealth Group (UNH) insider filing: This Form 4 reports that Patrick H. Conway, Chief Executive Officer, Optum, received 64.683 shares of UnitedHealth common stock on 09/23/2025 at no cost as dividend equivalents credited on outstanding restricted stock units. The entry shows these dividend equivalents are subject to the same vesting terms as the underlying restricted stock units and will be forfeited if those units do not vest. Following the reported transaction, Mr. Conway is shown as beneficially owning 10,536.194 shares (direct ownership). The filing was signed by an attorney-in-fact on behalf of Mr. Conway on 09/25/2025. The Form contains no option exercises, sales, or cash purchases; it discloses a routine issuance tied to compensation arrangements.
UnitedHealth Group (UNH) insider filing shows a small, non-cash award and details of the reporting person's holdings. On 09/23/2025 the filing reports acquisition of 50 shares as dividend equivalents on vested deferred stock units, recorded at a $0 price because they represent vested awards rather than open-market purchases. The form shows the reporting person holds 427,895.942 shares directly, plus 349.7439 shares indirectly in a 401(k) and 681,875 shares indirectly in trusts. Explanatory notes state certain trust-to-direct and direct-to-trust transfers occurred on August 14, 2025 and were exempt from reporting under Rule 16a-13.
Paul R. Garcia, a director of UnitedHealth Group Inc. (UNH), reported an internal acquisition on 09/23/2025 consisting of 11 common stock units recorded as acquired at $0 as dividend equivalents on vested deferred stock units. The filing shows 2,761 shares beneficially owned directly after the transaction and additional indirect holdings of 2,146 shares via a revocable trust plus 45 and 55 shares via two other trusts. The dividend equivalents vested immediately and carry the same terms as the underlying deferred stock units.
Timothy P. Flynn, a director of UnitedHealth Group Inc. (UNH), reported a Section 16 transaction dated 09/23/2025. The filing shows 61 shares of Common Stock were acquired as dividend equivalents on vested deferred stock units, with a reported price of $0. Following the transaction, Mr. Flynn beneficially owned 9,538 shares directly and 6,033 shares indirectly through a trust. The form was signed by an attorney-in-fact on 09/25/2025. The filing is a single-person Form 4 and lists Mr. Flynn's relationship to the issuer as a director.
Michele J. Hooper, a director of UnitedHealth Group (UNH), received 236 shares on 09/23/2025 as dividend equivalents tied to vested deferred stock units; the reporting indicates these dividend equivalents are immediately vested and carry the same terms as the underlying deferred stock units. After the transaction, Hooper beneficially owned 40,715 shares. The Form 4 was signed by an attorney-in-fact on 09/25/2025. No cash consideration was paid for the 236 shares, consistent with dividend-equivalent treatment.
Frederick W. McNabb III, a director of UnitedHealth Group Inc. (UNH), reported a transaction on Form 4 showing the acquisition of 49 shares of Common Stock on 09/23/2025 at no cash price. The filing explains these 49 shares represent dividend equivalents paid on vested deferred stock units, which are immediately vested and subject to the same terms as the underlying units. Following the transaction, Mr. McNabb beneficially owns 14,052 shares. The Form 4 was signed by an attorney-in-fact on 09/25/2025.
UnitedHealth Group (UNH) reporting person Charles D. Baker received 1,256 shares of common stock as dividend equivalents on vested deferred stock units. The shares were issued through an acquisition transaction coded A (dividend equivalents) on 09/23/2025 at no cash price ($0), and the ownership is held directly. The filing notes these dividend equivalents become immediately vested and carry the same terms as the underlying deferred stock units. The Form 4 was submitted by an attorney-in-fact on behalf of the reporting person.
John H. Noseworthy, M.D., a director of UnitedHealth Group Inc. (UNH), reported a non‑derivative acquisition on 09/23/2025. The filing shows 39 shares of Common Stock were acquired at a reported price of $0, described as dividend equivalents paid on vested deferred stock units that are immediately vested and subject to the same terms as the underlying deferred stock units. After the transaction, Dr. Noseworthy beneficially owned 6,432 shares of UNH. The Form 4 was signed by an attorney‑in‑fact on 09/25/2025.
Valerie C. Montgomery Rice M.D., a director of UnitedHealth Group Inc. (UNH), reported a non‑derivative acquisition of 40 shares of common stock on 09/23/2025. The shares were recorded as dividend equivalents on vested deferred stock units and carried a $0 price; the filing shows 6,627 shares owned after the transaction. The dividend equivalents are immediately vested and subject to the same terms as the underlying deferred stock units. The Form 4 was signed by attorney‑in‑fact Faraz A. Choudhry on 09/25/2025.
Erin L. McSweeney, Executive Vice President and Chief People Officer of UnitedHealth Group (UNH), reported a non‑cash acquisition on 09/23/2025 consisting of 36.837 shares of common stock recognized as dividend equivalents on outstanding restricted stock units. The reported price is $0 because these shares represent dividend equivalents rather than a market purchase. Following this issuance, McSweeney beneficially owns 11,154.072 shares. The filing notes the dividend equivalents follow the same vesting terms as the underlying restricted stock units and are forfeitable if those units do not vest.
Christopher R. Zaetta, EVP & Chief Legal Officer of UnitedHealth Group (UNH), received 42.53 dividend-equivalent shares on 09/23/2025 that were paid on outstanding restricted stock units and are subject to the same vesting and forfeiture terms as the underlying RSUs. The transaction was reported on a Form 4 executed by an attorney-in-fact on 09/25/2025. The reported shares were issued at a $0 price as dividend equivalents and increase the reporting person’s beneficial ownership to 10,283.276 shares following the transaction.
UnitedHealth Group (UNH) Form 4: This filing reports a non-derivative acquisition by Thomas E. Roos, Chief Accounting Officer, via an authorized filing on behalf of the reporting person. On 09/23/2025 the report shows an acquisition of 22.357 units recorded as dividend equivalents on outstanding restricted stock units, with a reported price of $0 because these are dividend-equivalent payments tied to RSUs and subject to the same vesting and forfeiture terms as the underlying awards. Following the transaction, the reporting person beneficially owned 29,593.519 shares, which includes shares acquired through UnitedHealth’s Employee Stock Purchase Plan. The filing was signed by an attorney-in-fact on 09/25/2025.